Aclarion, Inc. (ACON): Depreciation & Amortization
$227.4K
Year ended 2025-12-31
$242.5K
Trailing 12 months to 2026-06-30
+16.6%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $227.4K | +17.7% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $193.1K | +18.7% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $162.7K | +13.3% | 2025-04-09, From 2023-01-01 |
| 2022-12-31 | $143.6K | -22.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $186.4K | n/a | 2023-06-12, From 2021-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Aclarion, Inc. (ACON) | 2025-12-31 | $227.4K | +17.7% |
| Sera Prognostics, Inc. (SERA) | 2025-12-31 | $940.0K | +12.8% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $5.71M | -7.5% |
| Exagen Inc. (XGN) | 2025-12-31 | $2.10M | +23.5% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $10.05M | -8.2% |
| Biodesix Inc (BDSX) | 2025-12-31 | $5.67M | -1.8% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $6.90M | -1.4% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $24.12M | -3.2% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $40.77M | +154.9% |
Compare ACON, SERA, AMS, XGN side by side · Screen every company in Services-Medical Laboratories ↗